Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of California, San Francisco Kaiser Permanente |
---|---|
Information provided by: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT00328640 |
Is a secondary prevention intervention, focused on implementation of standardized pre-printed discharge orders for hospitalists, effective at increasing utilization of the following evidence-based treatments 6 months after discharge for ischemic stroke:
Condition | Intervention | Phase |
---|---|---|
Ischemic Stroke |
Drug: Optimal treatment |
Phase IV |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Single Blind, Placebo Control, Single Group Assignment, Safety Study |
Official Title: | Secondary Prevention After Ischemic Stroke: A Trial of an Evidence-Based System-Wide Intervention |
Estimated Enrollment: | 1500 |
Study Start Date: | December 2005 |
Study Completion Date: | March 2007 |
There are several proven strategies for prevention of recurrent ischemic stroke, including use of statins, treatment of hypertension, and anticoagulation in patients with atrial fibrillation. Preliminary analyses suggest that only 9-15% of Kaiser Permanente Northern California’s ischemic stroke patients receive optimal care for secondary prevention of stroke. The purpose of this study is to determine whether or not a quality improvement (QI) intervention can improve the care received by stroke patients. This project consists of a randomized trial of standardized stroke discharge order forms to improve adherence with best practices in secondary stroke prevention. The primary research question is: Is a secondary prevention intervention, focused on implementation of standardized pre-printed discharge orders for hospitalists, effective at increasing utilization of the following evidence-based treatments 6 months after discharge for ischemic stroke: (1) treatment with statins, (2) control of hypertension, and (3) anticoagulation in patients with atrial fibrillation.
The primary outcome will be the proportion of patients receiving optimal treatment, as defined by these three goals. The impact of the intervention will be measures as a change after-to-before at intervention hospitals compared to non-intervention (control) hospitals, with the institution as the unit of analysis. Secondary analyses will evaluate the impact of the intervention on each of these components and on 6-month and 1-year rates of mortality, readmission for stroke, and costs of care after discharge.
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Ischemic stroke Kaiser-Permanente Health Plan Member with Pharmacy Benefit Discharged alive to home
Exclusion Criteria:
tpA patients Hemorrhagic stroke TIA Significant comorbidities
United States, California | |
Kaiser-Permanente Division of Research | |
Oakland, California, United States, 94612 |
Study Director: | David M Grosvenor, MPH | University of California, San Francisco |
Principal Investigator: | S C Johnston, MD | University of California, San Francisco |
Study ID Numbers: | MM 0620 0404 |
Study First Received: | May 18, 2006 |
Last Updated: | April 25, 2007 |
ClinicalTrials.gov Identifier: | NCT00328640 |
Health Authority: | United States: Institutional Review Board |
CVA Ischemic stroke |
Cerebral Infarction Stroke Vascular Diseases Neoplasm Metastasis Brain Ischemia Central Nervous System Diseases |
Brain Infarction Ischemia Brain Diseases Infarction Cerebrovascular Disorders |
Pathologic Processes Nervous System Diseases Cardiovascular Diseases |